aml
No description yet: the sentence for this tag has not been written. 8 records carry it: 7 people, 1 biomarker.
Related tags
By kind
8 records
| Cancers | Other tags | ||||
|---|---|---|---|---|---|
Alexander E. Perl Professor of Medicine, Abramson Cancer Center, University of Pennsylvania · Abramson Cancer Center, University of Pennsylvania Led ADMIRAL, which made gilteritinib the standard for relapsed FLT3-mutant AML. | Acute myeloid leukaemia | none | flt3, targeted-therapy | ||
Andrew H. Wei Consultant Haematologist, Peter MacCallum Cancer Centre and Royal Melbourne Hospital; Professor, University of Melbourne · Peter MacCallum Cancer Centre Australian haematologist who led VIALE-C and QUAZAR AML-001, advancing venetoclax and oral azacitidine maintenance in AML. | Acute myeloid leukaemia | none | venetoclax, australia | ||
Courtney D. DiNardo Professor of Leukemia, MD Anderson Cancer Center · MD Anderson Cancer Center Led VIALE-A, which made venetoclax plus azacitidine the standard for older patients with acute myeloid leukaemia. | Acute myeloid leukaemia | none | venetoclax, trialist | ||
Eytan M. Stein Chief, Leukemia Service, Memorial Sloan Kettering Cancer Center · Memorial Sloan Kettering Cancer Center Led the enasidenib and revumenib trials that brought IDH2 and menin inhibitors to acute leukaemia. | Acute myeloid leukaemia, Acute lymphoblastic leukaemia | none | menin, idh, early-phase | ||
Ghayas C. Issa Associate Professor of Leukemia, MD Anderson Cancer Center · MD Anderson Cancer Center First author of the revumenib trial that created the menin inhibitor class for acute leukaemia. | Acute myeloid leukaemia, Acute lymphoblastic leukaemia | none | menin, targeted-therapy | ||
Hartmut Döhner Medical Director, Department of Internal Medicine III, Ulm University Hospital · Ulm University Hospital / Comprehensive Cancer Center Ulm Leads the European LeukemiaNet classification that defines how AML is diagnosed and risk-stratified worldwide. | Acute myeloid leukaemia | none | classification, guidelines | ||
NPM1 mutation NPM1 NPM1 mutations, found in about a third of adult acute myeloid leukaemias, misplace the nucleophosmin protein into the cytoplasm. They mean a better outlook without FLT3-ITD, a sensitive MRD marker, and since 2025 a targeted menin inhibitor. | Acute myeloid leukaemia, NPM1-mutated and KMT2A-rearranged acute myeloid leukaemia | none | biomarker | ||
Richard M. Stone Chief of Staff and Director of Translational Research, Adult Leukemia Program, Dana-Farber Cancer Institute · Dana-Farber Brigham Cancer Center Led RATIFY, the trial that made midostaurin the first targeted therapy added to induction chemotherapy for AML. | Acute myeloid leukaemia | none | flt3, cooperative-group |
